Blocking/cleavage of extracellular pathological forms, and overexpressing cell surface forms of vimentin by decoy peptides or antibodies can be one of the strategies to target vimentin in lung diseases such as autoimmune diseases, cancer, and infections. The gene discussed is VIM; the disease is autoimmune disease.